Search
urokinase plasminogen activator surface receptor; uPAR; U-PAR; monocyte activation antigen Mo3; CD87 (PLAUR, MO3, UPAR)
Function:
- receptor for urokinase plasminogen activator (uPA)
- role in localizing & promoting plasmin formation
- uPA bound to uPAR can lead to conversion of plasminogen to plasmin which becomes bound to adjacent plasma membrane receptors
- negatively regulated by uPA
- receptors for uPA & plasmin have been localized to leading edges of migrating leukocytes & tumor cells leading to enzymatic activity of plasmin (which is dependent on uPA) causing hydrolysis of surrounding extra-cellular matrix proteins; thus, uPAR expression & level of bound uPA have been implicated in inflammatory cell invasion & tumor cell metastasis [3]
- CD87 may also contribute to beta-2-integrin-dependent adherence & chemotaxis [3]
- interacts with MRC2
Structure:
- monomer (probable).
- contains 3 UPAR/Ly6 domains
Compartment:
- isoform 1: cell membrane; lipid-anchor, GPI-anchor
- isoform 2: secreted (probable)
Alternative splicing: named isoforms=3
Expression:
- T cells
- NK cells
- monocytes
- myeloid cells, neutrophils
- dendritic cells
- endothelial cells
- fibroblasts
- smooth muscle cells
- keratinocytes
- placental trophoblasts
- hepatocytes
- bronchial epithelium (low levels) [5]
* expression may be related to inflammation, complement activation, coagulation & TGF-beta signaling [5]
Pathology:
- breast carcinoma
- colon carcinoma
- prostate carcinoma
- melanoma
- may have role in metastases
- expression may be related to inflammation, complement activation, coagulation & TGF-beta signaling [5]
- putative role in human aging
- plasma soluble UPAR positively correlates with the rate of aging in humans [5]
- age-related increase in UPAR in liver, adipose tissue, skeletal muscle & pancreas [5]
- parallel increase in senecence-associated beta-galactosidase
Pharmacology:
- clearance of cell surface uPAR-containing cells* with CAR T-cell therapy may prevent &/or attenuate age-related degenerative pathology [5]
* uPAR is a putative biomarker of senescent cells [5]
Laboratory:
- elevated plasma soluble urokinase plasminogen activator receptor may be used to assess indication for anakinra in treatment of Covid-19 pneumonia
Related
plasminogen activator
General
cluster-of-differentiation antigen; cluster designation antigen; CD antigen
cell surface receptor
glypiated protein
Properties
SIZE: entity length = 335 aa
MW = 37 kD
COMPARTMENT: plasma membrane
CELL-REGION: apical region
CELL: epithelial cell
MOTIF: signal sequence {1-22}
UPAR/Ly6 1 {23-114}
MOTIF: cysteine residue {C25}
MODIFICATION: cysteine residue {C46}
cysteine residue {C28}
MODIFICATION: cysteine residue {C34}
cysteine residue {C34}
MODIFICATION: cysteine residue {C28}
cysteine residue {C39}
MODIFICATION: cysteine residue {C67}
cysteine residue {C46}
MODIFICATION: cysteine residue {C25}
cysteine residue {C67}
MODIFICATION: cysteine residue {C39}
N-glycosylation site {N74}
cysteine residue {C93}
MODIFICATION: cysteine residue {C98}
cysteine residue {C98}
MODIFICATION: cysteine residue {C93}
peptide motif {105-106}
peptide motif {111-112}
UPAR/Ly6 2 {115-213}
MOTIF: cysteine residue {C117}
MODIFICATION: cysteine residue {C144}
cysteine residue {C120}
MODIFICATION: cysteine residue {C127}
cysteine residue {C127}
MODIFICATION: cysteine residue {C120}
cysteine residue {C137}
MODIFICATION: cysteine residue {C169}
cysteine residue {C144}
MODIFICATION: cysteine residue {C117}
cysteine residue {C169}
MODIFICATION: cysteine residue {C137}
cysteine residue {C175}
MODIFICATION: cysteine residue {C192}
N-glycosylation site {N184}
cysteine residue {C192}
MODIFICATION: cysteine residue {C175}
cysteine residue {C193}
MODIFICATION: cysteine residue {C198}
N-glycosylation site {N194}
cysteine residue {C198}
MODIFICATION: cysteine residue {C193}
UPAR/Ly6 3 {214-305}
MOTIF: cysteine residue {C216}
MODIFICATION: cysteine residue {C244}
cysteine residue {C219}
MODIFICATION: cysteine residue {C227}
N-glycosylation site {N222}
cysteine residue {C227}
MODIFICATION: cysteine residue {C219}
cysteine residue {C237}
MODIFICATION: cysteine residue {C263}
cysteine residue {C244}
MODIFICATION: cysteine residue {C216}
N-glycosylation site {N255}
cysteine residue {C263}
MODIFICATION: cysteine residue {C237}
cysteine residue {C269}
MODIFICATION: cysteine residue {C287}
cysteine residue {C287}
MODIFICATION: cysteine residue {C269}
cysteine residue {C288}
MODIFICATION: cysteine residue {C293}
cysteine residue {C293}
MODIFICATION: cysteine residue {C288}
glycosyl phosphatidylinositol [GPI] membrane anchor {N305}
Database Correlations
OMIM 173391
UniProt Q03405
Pfam PF00021
Entrez Gene 5329
KEGG correlations
References
- UniProt :accession Q03405
- http://www.pathologyoutlines.com/cdmarkers.html
20 May 2003
- Protein Reviews on the Web
http://mpr.nci.nih.gov/prow/guide/1928485002_g.htm
- SeattleSNPs
http://pga.gs.washington.edu/data/plaur/
- Amor C, Fernandez-Maestre I, Chowdhury S et al
Prophylactic and long-lasting efficacy of senolytic CAR T cells against
age-related metabolic dysfunction.
Nat Aging. 2024 Jan 24.
PMID: 38267706
https://www.nature.com/articles/s43587-023-00560-5